The Latest Cardiac and Vascular News
BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization…
Clinical investigators achieve significant milestone by enrolling 150 patients with hypervascular tumors in pivotal randomized study. BEDFORD, Mass., May 14, 2024 /PRNewswire/ — Instylla, Inc., a privately held clinical-stage company focused on developing liquid embolics for peripheral…
BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with continued participation from […]
Pivotal study to evaluate Embrace™ Hydrogel Embolic System for the embolization of arterial bleeds in the peripheral vasculature BEDFORD, Mass., Jan. 10, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment […]
BEDFORD, Mass., July 26, 2022 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models. In a Journal of Vascular […]
Prospective multicenter study evaluated the safety and efficacy of a PEG-based liquid embolic in treating hypervascular tumors BEDFORD, Mass., March 15, 2022 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of resultsi from […]
